Harmony Biosciences Reports Promising Phase 3 Data for EPX-100 in Dravet Syndrome

Reuters12-08

<a href="https://laohu8.com/S/HRMY">Harmony Biosciences</a> Reports Promising Phase 3 Data for EPX-100 in Dravet Syndrome

Harmony Biosciences Holdings Inc. has announced initial data from the open-label extension (OLE) of its ongoing Phase 3 ARGUS trial, which is evaluating EPX-100 (clemizole hydrochloride) for the treatment of Dravet syndrome. The data, to be presented at the 2025 American Epilepsy Society Annual Meeting in December, showed that participants with at least six months of exposure to EPX-100 experienced a median reduction of approximately 50% in countable motor seizure frequency per 28 days. Half of the participants achieved at least a 50% reduction in seizure frequency. EPX-100 was generally well-tolerated, with the most common adverse events being seizures, pyrexia, and upper respiratory tract infection. No significant gastrointestinal adverse events were reported. The ARGUS and LIGHTHOUSE trials for EPX-100 are ongoing, with topline data from ARGUS expected in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208200920) on December 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589353622?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589353622","market":"fut","top_or_hot":-1,"title":"Harmony Biosciences Reports Promising Phase 3 Data for EPX-100 in Dravet Syndrome","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/HRMY\">Harmony Biosciences</a> Reports Promising Phase 3 Data for EPX-100 in Dravet Syndrome\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Harmony Biosciences Holdings Inc. has announced initial data from the open-label extension (OLE) of its ongoing Phase 3 ARGUS trial, which is evaluating EPX-100 (clemizole hydrochloride) for the treatment of Dravet syndrome. The data, to be presented at the 2025 American Epilepsy Society Annual Meeting in December, showed that participants with at least six months of exposure to EPX-100 experienced a median reduction of approximately 50% in countable motor seizure frequency per 28 days. Half of the participants achieved at least a 50% reduction in seizure frequency. EPX-100 was generally well-tolerated, with the most common adverse events being seizures, pyrexia, and upper respiratory tract infection. No significant gastrointestinal adverse events were reported. The ARGUS and LIGHTHOUSE trials for EPX-100 are ongoing, with topline data from ARGUS expected in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208200920) on December 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harmony Biosciences Reports Promising Phase 3 Data for EPX-100 in Dravet Syndrome</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarmony Biosciences Reports Promising Phase 3 Data for EPX-100 in Dravet Syndrome\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-08 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/HRMY\">Harmony Biosciences</a> Reports Promising Phase 3 Data for EPX-100 in Dravet Syndrome\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Harmony Biosciences Holdings Inc. has announced initial data from the open-label extension (OLE) of its ongoing Phase 3 ARGUS trial, which is evaluating EPX-100 (clemizole hydrochloride) for the treatment of Dravet syndrome. The data, to be presented at the 2025 American Epilepsy Society Annual Meeting in December, showed that participants with at least six months of exposure to EPX-100 experienced a median reduction of approximately 50% in countable motor seizure frequency per 28 days. Half of the participants achieved at least a 50% reduction in seizure frequency. EPX-100 was generally well-tolerated, with the most common adverse events being seizures, pyrexia, and upper respiratory tract infection. No significant gastrointestinal adverse events were reported. The ARGUS and LIGHTHOUSE trials for EPX-100 are ongoing, with topline data from ARGUS expected in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208200920) on December 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HRMY","symbol_name":"Harmony Biosciences Holdings, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL76YTwB:1","article_id":"2589353622","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589353622","pubTimestamp":1765199125,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Harmony Biosciences Holdings Inc. has announced initial data from the open-label extension  of its ongoing Phase 3 ARGUS trial, which is evaluating EPX-100  for the treatment of Dravet syndrome. The data, to be presented at the 2025 American Epilepsy Society Annual Meeting in December, showed that participants with at least six months of exposure to EPX-100 experienced a median reduction of approximately 50% in countable motor seizure frequency per 28 days. Half of the participants achieved at least a 50% reduction in seizure frequency. EPX-100 was generally well-tolerated, with the most common adverse events being seizures, pyrexia, and upper respiratory tract infection. No significant gastrointestinal adverse events were reported. The ARGUS and LIGHTHOUSE trials for EPX-100 are ongoing, with topline data from ARGUS expected in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timel","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HRMY":"Harmony Biosciences Holdings, Inc.","BK4007":"制药"},"translate_title":"Harmony Biosciences报告了EPX-100治疗Dravet综合征的有希望的3期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HRMY":0.9},"content_text":"Harmony Biosciences Reports Promising Phase 3 Data for EPX-100 in Dravet Syndrome\n    \n\n        Harmony Biosciences Holdings Inc. has announced initial data from the open-label extension (OLE) of its ongoing Phase 3 ARGUS trial, which is evaluating EPX-100 (clemizole hydrochloride) for the treatment of Dravet syndrome. The data, to be presented at the 2025 American Epilepsy Society Annual Meeting in December, showed that participants with at least six months of exposure to EPX-100 experienced a median reduction of approximately 50% in countable motor seizure frequency per 28 days. Half of the participants achieved at least a 50% reduction in seizure frequency. EPX-100 was generally well-tolerated, with the most common adverse events being seizures, pyrexia, and upper respiratory tract infection. No significant gastrointestinal adverse events were reported. The ARGUS and LIGHTHOUSE trials for EPX-100 are ongoing, with topline data from ARGUS expected in 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208200920) on December 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589353622","isCrawlerRequest":true}